Q32 Bio Inc. (0T6G)
LSE 
Summary
0T6G Chart
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock?
Q32 Bio (QTTB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.
Q32 Bio Inc. (0T6G) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Q32 Bio Inc. ever had a stock split?
Q32 Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jodie Pope Morrison CEO | LSE Exchange | US7469641051 ISIN |
| US Country | 28 Employees | - Last Dividend | 26 Mar 2024 Last Split | - IPO Date |
Overview
Q32 Bio Inc. is a pioneering force within the realm of clinical-stage biotechnology, specifically targeting the intricate realms of autoimmune and inflammatory diseases through the development of innovative biologic therapeutics. These therapeutics are expertly designed to modulate the essential regulators of two critical components of the human immune system: the innate and the adaptive systems. The objective behind their groundbreaking research and product development is to restore a harmonious balance within the body's immunity, aiming to offer relief and potential cures to individuals suffering from these debilitating conditions. Originally established under the name AdMIRx Inc., the enterprise underwent a strategic rebranding, adopting the name Q32 Bio Inc. in April 2020. This rebranding marked a new chapter in the company's journey since its inception in 2017. Operating from its headquarters in Waltham, Massachusetts, Q32 Bio is steadfast in its mission to advance the field of immunotherapy through its innovative approach to drug development.
Products and Services
- ADX-914 - A human anti-IL-7R antibody
ADX-914 stands at the forefront of Q32 Bio's ambitious pipeline, showcasing a novel approach to rebalancing the adaptive immune function. This therapeutic antibody specifically targets the IL-7 receptor, which plays a pivotal role in the pathogenesis of several autoimmune and inflammatory diseases. By modulating this receptor, ADX-914 aims to restore immune equilibrium, potentially offering a significant therapeutic benefit for patients afflicted by these conditions.
- ADX-097 - Targeted Therapeutic Modulation
As an integral component of Q32 Bio's innovative portfolio, ADX-097 embodies a cutting-edge approach to drug delivery and efficacy. Engineered to achieve optimal biodistribution to tissues and organs affected by autoimmune and inflammatory diseases, this product is designed to ensure durable pharmacokinetics and pharmacodynamics. The robust efficacy demonstrated by ADX-097 in preclinical models accentuates its potential to revolutionize the treatment landscape for patients battling these chronic conditions.
Contact Information
